
A short seller is challenging Praxis Precision Medicines Inc. (NASDAQ:PRAX) after the company claimed success from its Phase 3 trial of ulixacaltamide.
- PRAX shares are retreating from recent levels. Watch the momentum here

A short seller is challenging Praxis Precision Medicines Inc. (NASDAQ:PRAX) after the company claimed success from its Phase 3 trial of ulixacaltamide.